SCIENTIFIC publications

/cun/en/investigacion/publicaciones-cientificas/areaMain/02
  • Classification of Vestibular Signs and Examination Techniques: Nystagmus and Nystagmus-like Movements

    Eggers SDZ (1), Bisdorff A (2), von Brevern M (3), Zee DS (4), Kim JS (5), Perez-Fernandez N (6), Welgampola MS (7), Della Santina CC (8), Newman-Toker DE (4,8).

    (1) Department of Neurology, Mayo Clinic, Rochester, MN, USA.
    (2) Department of Neurology, Centre Hospitalier Emile Mayrisch, Esch-sur-Alzette, Luxembourg.
    (3) Private Practice of Neurology and Department of Neurology, Charité, Berlin, Germany.
    (4) Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, USA.
    (5) Department of Neurology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seoul, Korea.
    (6) Department of Otorhinolaryngology, Clínica Universidad de Navarra, Madrid, Spain.
    (7) Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Central Clinical School, University of Sydney, Sydney, Australia.
    (8) Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, USA.

    Journal of Vestibular Research 14 JUNE 2019

  • Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus

    Soria-Juan B (1), Escacena N (2), Capilla-González V (2), Aguilera Y (2), Llanos L (1), Tejedo JR (2,3), Bedoya FJ (2,3), Juan V (4), De la Cuesta A (5), Ruiz-Salmerón R (6), Andreu E (7), Grochowicz L (7), Prósper F (7), Sánchez-Guijo F (8), Lozano FS (8), Miralles M (9), Del Río-Solá L (10), Castellanos G (11), Moraleda JM (11), Sackstein R (12), García-Arranz M 1, García-Olmo D (1), Martín F (2,3), Hmadcha A (2,3), Soria B (2,3); Collaborative Working Group “Noma Project Team”.

    (1) Fundación Jiménez Díaz Health Research Institute, Madrid, Spain.
    (2) Department of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, Spain.
    (3) Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain.
    (4) Andalusian eHealth Library, Sevilla, Spain.
    (5) Unidad de Isquemia Crónica de Miembros Inferiores, Hospital Victoria Eugenia de la Cruz Roja, Sevilla, Spain.
    (6) Servicio de Cardiología, Hospital Universitario Virgen Macarena, Sevilla, Spain.
    (7) Clínica Universidad de Navarra, Pamplona, Spain.
    (8) IBSAL-Hospital Universitario Salamanca, Salamanca, Spain.
    (9) Department of Surgery, University of Valencia, Valencia, Spain.
    (10) Cirugía Vascular, Hospital Universitario de Valladolid, Valladolid, Spain.
    (11) Servicio Hematología y Hemoterapia, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
    (12) Herbert Wertheim College of Medicine, Florida International University, Miami, FL, United States.

    Frontiers in Immunology 04 JUNE 2019

  • Circulating GDF11 levels are decreased with age but are unchanged with obesity and type 2 diabetes

    Añón-Hidalgo J (1), Catalán V (1,2,3), Rodríguez A (1,2,3), Ramírez B (1,2,3), Silva C (2,3,4), Galofré JC (4), Salvador J (2,4), Frühbeck G (1,2,3,4), Gómez-Ambrosi J (1,2,3).

    (1) Metabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain.
    (2) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Pamplona, Spain.
    (3) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
    (4) Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, Pamplona, Spain.

    Aging 21 MARCH 2019

  • Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

    Borrero-Palacios A (1), Cebrián A (2), Gómez Del Pulgar MT (1), García-Carbonero R (3), García P (4), Aranda E (5), Elez E (6), López-López R (7), Cervantes A (8), Valladares M (9), Nadal C (10), Viéitez JM (11), Guillén-Ponce C (12), Rodríguez J (13), Hernández I (14), García JL (15), Vega-Bravo R (16), Puime-Otin A (16), Martínez-Useros J (1), Del Puerto-Nevado L (1), Rincón R (1), Rodríguez-Remírez M (1), Rojo F (16), García-Foncillas J (17).

    (1) Translational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
    (2) Translational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
    (3) Medical Oncology Department, Hospital Virgen del Rocío, Sevilla, Spain.
    (4) Medical Oncology Department, Hospital Gral. Univ. Gregorio Marañón, Madrid, Spain.
    (5) Medical Oncology Department, Hospital Universitario Reina Sofía, Córdoba, Spain.
    (6) Medical Oncology Department, Hospital Vall d'Hebrón, Barcelona, Spain.
    (7) Medical Oncology Department, Complexo Hospitalario Universitario Santiago de Compostela, Galicia, Spain.
    (8) Medical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
    (9) Medical Oncology Department, Complejo Hospitalario Universitario A Coruña, Galicia, Spain.
    (10) Medical Oncology Department, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain.
    (11) Medical Oncology Department, Hospital Universitario Central de Asturias, Asturias, Spain.
    (12) Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
    (13) Medical Oncology Department, Clínica Universitaria de Navarra, Navarra, Spain.
    (14) Medical Oncology Department, Complejo Hospitalario de Navarra, Navarra, Spain.
    (15) Oncology, Medical Unit, Merck S.L, an affiliate of Merck KGaA, Darmstadt, Germany.
    (16) Anatomopathology Department, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
    (17) Translational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.

    Scientific Reports 20 FEBRUARY 2019

  • CT screening for lung cancer: comparison of three baseline screening protocols

    Henschke CI (1,2,3), Yip R (4), Ma T (4,5), Aguayo SM (6), Zulueta J (7), Yankelevitz DF (4); Writing Committee for the I-ELCAP Investigators.

    (1) Icahn School of Medicine at Mount Sinai, New York, NY, USA. Claudia.
    (2) Phoenix Veterans Affairs Health Care System, Phoenix, AZ, USA. Claudia.
    (3) Department of Radiology, Mount Sinai School of Medicine, 1 Gustave Levy Place, New York, NY, 10029, USA. Claudia.
    (4) Icahn School of Medicine at Mount Sinai, New York, NY, USA.
    (5) Department of Diagnostic Ultrasound, Tong Ren Hospital, Capital Medical University, Beijing, 100730, China.
    (6) Phoenix Veterans Affairs Health Care System, Phoenix, AZ, USA.
    (7) Clinica Universidad de Navarra, University of Navarra School of Medicine, Pamplona, Navarra, Spain.

    European Radiology 03 DECEMBER 2018

you mayBE INTERESTED

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra